. . . Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762 July 08, 2024 8:00 AM EDT | Source: Phio Pharmaceuticals Corp. Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts--(Newsfile Corp. - July 8, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, t ...

Marlborough, Massachusetts--(Newsfile Corp. - July 2, 2024) - Phio Pharmaceuticals Corp. (Nasdaq: PHIO) (the "Company"), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1- for-9. The reverse stock split will become effective at 12:01 a.m. Eastern Time on Ju ...

Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) Phio to present a clinical study progress update on their lead clinical candidate, PH-762 May 23, 2024 5:00 PM EDT | Source: Phio Pharmaceuticals Corp. Marlborough, Massachusetts--(Newsfile Corp. - May 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more e ...

MARLBOROUGH, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it has entered into a purchase agreement with TRITON Funds. Subject to the terms of the purchase agreement, TRITON will purchase up to approximately 18.8% of Phio's common shares yielding gross proceeds of up to $621,000 to the Co ...

MARLBOROUGH, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it has entered into a purchase agreement with TRITON Funds. Subject to the terms of the purchase agreement, TRITON will purchase up to approximately 18.8% of Phio's common shares yielding gross proceeds of up to $621,000 to the Co ...

MARLBOROUGH, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting data about its lead clinical candidate, PH-762, an INTASYL compound. The data is being presented in three posters at the annual meeting of the Society for Investigative Dermatology (SID) this week in Dallas, Texas. ...

About Phio Pharmaceuticals Corp. Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. For ...

[Phio Pharmaceuticals Q1 2024 Results and Business Update](index=1&type=section&id=Phio%20Pharmaceuticals%20Reports%20Q1%202024%20Results%20and%20Provides%20Business%20Update) [Recent Corporate Updates](index=1&type=section&id=Recent%20Corporate%20Updates) The company advanced its PH-762 clinical trial, presented positive preclinical data, and secured a new US patent - The Phase 1b clinical study for PH-762 is now active at four US sites, with **three patients enrolled** to evaluate its safety and tolerability in treating various skin cancers[2](index=2&type=chunk)[5](index=5&type=chunk) - Presented new preclinical data at two conferences, showcasing the potential of **PH-905 to improve NK cell function** and **PH-762 to inhibit tumor growth**[5](index=5&type=chunk) - The USPTO granted a patent for INTASYL Compounds RXI-185 and RXI-231, targeting proteins associated with **age-related skin disorders**[5](index=5&type=chunk) [Q1 2024 Financial Results](index=1&type=section&id=Financial%20Results) The company significantly reduced its net loss to $2.2 million, driven by lower R&D and G&A expenses [Cash Position](index=1&type=section&id=Cash%20Position) Cash reserves decreased to $6.5 million at quarter-end, reflecting a cash burn of $2.0 million Cash Position Comparison | Date | Cash (in millions) | | :--- | :--- | | March 31, 2024 | $6.5 | | December 31, 2023 | $8.5 | [Research and Development Expenses](index=1&type=section&id=Research%20and%20Development%20Expenses) R&D expenses decreased by 46% YoY to $1.1 million due to cost rationalization and a strategic shift R&D Expense Comparison (YoY) | Period | R&D Expenses (in millions) | Change | | :--- | :--- | :--- | | Q1 2024 | $1.1 | -46% | | Q1 2023 | $2.1 | | - The decrease was primarily driven by the company's transition from a discovery research to a product development company, resulting in lower costs for preclinical studies, salaries, and lab supplies[5](index=5&type=chunk) [General and Administrative Expenses](index=2&type=section&id=General%20and%20Administrative%20Expenses) G&A expenses declined 28% YoY to $1.1 million, mainly from lower consulting and legal costs G&A Expense Comparison (YoY) | Period | G&A Expenses (in millions) | Change | | :--- | :--- | :--- | | Q1 2024 | $1.1 | -28% | | Q1 2023 | $1.5 | | [Net Loss](index=2&type=section&id=Net%20Loss) Net loss narrowed to $2.2 million ($0.47 per share) from $3.6 million in the prior-year period Net Loss Comparison (YoY) | Metric | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Net Loss | $2.2 million | $3.6 million | | Net Loss Per Share | ($0.47) | ($3.15) | [Condensed Consolidated Financial Statements](index=3&type=section&id=Condensed%20Consolidated%20Financial%20Statements) Unaudited statements show total assets of $6.85 million and a net loss of $2.15 million for the quarter [Condensed Consolidated Statements of Operations](index=3&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20OPERATIONS) The company reported a Q1 operating loss of $2.21 million and a net loss of $2.15 million Condensed Consolidated Statements of Operations (Unaudited, in thousands) | | Three Months Ended March 31, | | :--- | :--- | :--- | | | **2024** | **2023** | | **Operating expenses:** | | | | Research and development | $1,148 | $2,134 | | General and administrative | $1,061 | $1,468 | | **Total operating expenses** | **$2,209** | **$3,602** | | **Operating loss** | **($2,209)** | **($3,602)** | | Total other income, net | $55 | $– | | **Net loss** | **($2,154)** | **($3,602)** | | **Net loss per common share** | **($0.47)** | **($3.15)** | [Condensed Consolidated Balance Sheets](index=3&type=section&id=CONDENSED%20CONSOLIDATED%20BALANCE%20SHEETS) Total assets stood at $6.85 million and stockholders' equity at $5.60 million as of March 31, 2024 Condensed Consolidated Balance Sheets (Unaudited, in thousands) | | **March 31, 2024** | **December 31, 2023** | | :--- | :--- | :--- | | **ASSETS** | | | | Cash and cash equivalents | $6,475 | $8,490 | | Prepaid expenses and other current assets | $373 | $832 | | **Total assets** | **$6,853** | **$9,364** | | **LIABILITIES AND STOCKHOLDERS' EQUITY** | | | | Total liabilities | $1,249 | $1,634 | | Total stockholders' equity | $5,604 | $7,730 | | **Total liabilities and stockholders' equity** | **$6,853** | **$9,364** |

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36304 Phio Pharmaceuticals Corp. (Exact name of registrant as specified in its charter) Delaware 45-3215903 (State or ot ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 45-3215903 (I.R.S. Employer Identification No.) 11 Apex Drive, Suite 300A PMB 2006, Marlborough, Massachusetts 01752 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ...